Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentosan polysulfate in mucopolysaccharidosis type I
ACTRN12620000823976Phase 2Recruiting
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- Sep 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of pentosan polysulfate sodium in mucopolysaccharidosis type I (2 cohorts), sponsored by Paradigm Biopharmaceuticals. Primary endpoint: Safety. Started Sep 2020; status: recruiting.
02
Drugs
pentosan polysulfate sodium
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on ACTRN12620000823976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000823976.